Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avenue Therapeutics Inc (ATXI)
NASDAQ:ATXI
RESEARCH TOOLSreports
Avenue Therapeutics (ATXI) Stock Price & Analysis
278 Followers
ATXI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.11 - $1.25
Previous Close$0.13
Volume283.57K
Average Volume (3M)1.51M
Market Cap
$5.93M
Enterprise Value$3.22M
Total Cash (Recent Filing)$1.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)>-0.1
Beta-0.77
Next Earnings
May 13, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding44,260,667
10 Day Avg. Volume786,308
30 Day Avg. Volume1,512,755
Standard Deviation0.36
R-Squared0.00133
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$0.75Price Target Upside459.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Avenue Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementThe trial for AJ201 in Spinal and Bulbar Muscular Atrophy is fully enrolled, setting the stage for potential breakthroughs in rare disease treatment.
Drug Development ProgressIV tramadol could help address the limitation by providing a safer but effective option positioned as a schedule IV opioid with reduced abuse potential.
Regulatory MilestoneFirst Oral Penem Approval in US is One Step Closer as Sulopenem REASSURE Study Successful; NDA Refiling 2Q24
Bears Say
Financial RestructuringConvertible Debt Restructuring Agreement & Potential Equity Funding Subject to Shareholder Vote
Financial RiskValuation includes an 80% revenue risk adjustment based on stage of development and clinical trial risk
Stock ValuationShare Price Exceeds analyst's Price Target – Downgrading to Hold
---
Ownership Overview
14.99% Insiders
0.22% Mutual Funds
0.11% Other Institutional Investors
84.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATXI FAQ
What was Avenue Therapeutics Inc’s price range in the past 12 months?
Avenue Therapeutics Inc lowest stock price was $0.11 and its highest was $1.25 in the past 12 months.
What is Avenue Therapeutics Inc’s market cap?
Currently, no data Available
When is Avenue Therapeutics Inc’s upcoming earnings report date?
Avenue Therapeutics Inc’s upcoming earnings report date is May 13, 2024 which is in 19 days.
How were Avenue Therapeutics Inc’s earnings last quarter?
Avenue Therapeutics Inc released its earnings results on Mar 18, 2024. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.95.
Is Avenue Therapeutics Inc overvalued?
According to Wall Street analysts Avenue Therapeutics Inc’s price is currently Undervalued.
Does Avenue Therapeutics Inc pay dividends?
Avenue Therapeutics Inc does not currently pay dividends.
What is Avenue Therapeutics Inc’s EPS estimate?
Avenue Therapeutics Inc’s EPS estimate is -$0.12.
How many shares outstanding does Avenue Therapeutics Inc have?
Avenue Therapeutics Inc has 44,260,666 shares outstanding.
What happened to Avenue Therapeutics Inc’s price movement after its last earnings report?
Avenue Therapeutics Inc reported an EPS of $0.85 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Avenue Therapeutics Inc?
Currently, no hedge funds are holding shares in ATXI
---
Avenue Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.75 (459.70% Upside)
$0.75 (459.70% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.2%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.99%
12-Months-Change
Fundamentals
Return on Equity
-378.24%
Trailing 12-Months
Asset Growth
-72.97%
Trailing 12-Months
Company Description
Avenue Therapeutics Inc
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
---
ATXI Stock 12 Months Forecast
Average Price Target
$0.75
▲(459.70% Upside)
Technical Analysis
Best Analysts Covering ATXI
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-9.40%
reiterated a buy rating 22 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.40% per trade.
---